VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 23,550 Shares of Moderna, Inc. $MRNA

VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 64.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 60,150 shares of the company’s stock after buying an additional 23,550 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Moderna were worth $1,774,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. MUFG Securities EMEA plc bought a new position in Moderna in the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new stake in Moderna in the 4th quarter worth approximately $31,000. Ameriflex Group Inc. lifted its stake in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after purchasing an additional 1,208 shares in the last quarter. Cromwell Holdings LLC lifted its stake in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Moderna from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. The Goldman Sachs Group increased their target price on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research report on Friday, May 1st. Royal Bank Of Canada raised their price objective on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research report on Monday, May 4th. Finally, Barclays raised their price objective on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research report on Thursday, April 2nd. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $35.73.

Moderna Price Performance

MRNA stock opened at $49.04 on Friday. The firm’s 50-day moving average price is $51.56 and its two-hundred day moving average price is $40.86. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55. The stock has a market capitalization of $19.46 billion, a price-to-earnings ratio of -6.02 and a beta of 1.05. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to analysts’ expectations of $236.37 million. During the same quarter in the previous year, the firm posted ($2.52) EPS. Moderna’s revenue was up 260.2% compared to the same quarter last year. As a group, equities analysts predict that Moderna, Inc. will post -6.79 earnings per share for the current year.

Insider Transactions at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. The trade was a 32.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 160,009 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the sale, the president owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. This trade represents a 9.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.